Archives of Virology

, Volume 138, Issue 3–4, pp 315–330

Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression

  • N. Jin
  • S. Funahashi
  • H. Shida
Original Papers


We devised vaccinia virus (VV)-based vector systems that support higher levels of expression of cloned genes in the early and late phases of the infection cycle than reported previously. Enhanced expression can be obtained by combining the promoter of the A-type inclusion body protein gene, the mutated early region of the 7.5-kDa gene promoter (7.5-kDa promoter), and the promoter of the hemagglutinin (HA) gene. One construct produced 60 µg/106 cells of chloramphenicol acetyltransferase (CAT), equivalent to 10–18% of total cell protein. Another construct produced about seven times more CAT during the early phase than the amount synthesized under the control of the 7.5-kDa promoter alone. The envelope proteins of human immunodeficiency virus type I synthesized during the early phase of infection were more active as immunogens than these proteins synthesized during the late phase, regardless of the amounts produced.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284–291PubMedGoogle Scholar
  2. 2.
    Alcami A, Smith GL (1992) A soluble receptor for interleukin-1 β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71: 153–167PubMedGoogle Scholar
  3. 3.
    Alexander WA, Moss B, Fuerst TR (1992) Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol 66: 2934–2942PubMedGoogle Scholar
  4. 4.
    Chesebro B, Wehrly K (1988) Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 62: 3779–3788PubMedGoogle Scholar
  5. 5.
    Coupar BEH, Andrew ME, Both GW, Boyle DB (1986) Temporal regulation of hemagglutinin expression in vaccinia virus recombinant and effects on the immune response. Eur J Immunol 16: 1479–1487PubMedGoogle Scholar
  6. 6.
    Davison AJ, Moss B (1989a) Structure of vaccinia virus late promoters. J Mol Biol 210: 771–784PubMedGoogle Scholar
  7. 7.
    Davison AJ, Moss B (1989b) Structure of vaccinia virus early promoters. J Mol Biol 210: 749–769PubMedGoogle Scholar
  8. 8.
    Earl PL, Doms PW, Moss B (1990) Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 87: 648–652PubMedGoogle Scholar
  9. 9.
    Elroy-Stein O, Fuerst TR, Moss B (1989) Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5′ sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid expression system. Proc natl Acad Sci USA 86: 6126–6130PubMedGoogle Scholar
  10. 10.
    Fathi Z, Sridhar P, Pacha RF, Condit RC (1986) Efficient targeted insertion of an unselected marker into the vaccinia virus genome. Virology 155: 97–105PubMedGoogle Scholar
  11. 11.
    Fuerst TR, Earl PL, Moss B (1987) use of hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol 7: 2538–2544PubMedGoogle Scholar
  12. 12.
    Funahashi S, Itamura S, Linuma H, Nerome K, Sugimoto M, Shida H (1991) Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses. J Virol 65: 5584–5588PubMedGoogle Scholar
  13. 13.
    Funahashi S, Sato T, Shida H (1988) Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus. J Gen Virol 69: 35–47PubMedGoogle Scholar
  14. 14.
    Gorman CM, Moffat LF, Howard BH (1982) Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol 2: 1044–1051PubMedGoogle Scholar
  15. 15.
    Hu S-L, Kosowski SG, Schaaf KF (1987) Expression of envelope glycoproteins of human immunodeficiency virus by an insect virus vector. J Virol 61: 3617–3620PubMedGoogle Scholar
  16. 16.
    Ichihashi Y, Dales S (1973) Biogenesis of poxviruses: relationship between a translation complex and formation of A-type inclusions. Virology 51: 297–319PubMedGoogle Scholar
  17. 17.
    Itamura S, Iinuma H, Shida H, Morikawa Y, Nerome K, Oya A (1990) Characterization of antibody and cytotoxic T lymphocyte responses to human influenza virus H3 haemagglutinin locus of vaccinia virus. J Gen Virol 71: 2859–2865PubMedGoogle Scholar
  18. 18.
    Klaniecki J, Dykers T, Travis B, Schmitt R, Wain M, Watson A, Sridhar P, Mcclure J, Morein B, Ulrich JT, Hu S-L, Lewis J (1991) Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus. AIDS Res Hum Retroviruses 7: 791–798PubMedGoogle Scholar
  19. 19.
    Kotwal GJ, Isaacs SN, Mckenzie R, Frank MM, Moss B (1990) Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250: 827–830PubMedGoogle Scholar
  20. 20.
    Mackett M, Smith GL, Moss B (1982) Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79: 7415–7419PubMedGoogle Scholar
  21. 21.
    Maeda S, Kawai T, Obinata M, Fujiwara H, Horiuchi T, Saeki Y, Sato Y, Furusawa M (1985) Production of human α-interferon in silkworm using a baculovirus vector. Nature 315: 592–594PubMedGoogle Scholar
  22. 22.
    Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79: 4927–4931PubMedGoogle Scholar
  23. 23.
    Patel DD, Pickup DJ, Joklik WK (1986) Isolation of cowpox virus A-type inclutions and characterization of their major protein component. Virology 149:174–189PubMedGoogle Scholar
  24. 24.
    Patel DD, Ray CA, Drucker RP, Pickup DJ (1988) A poxvirus derived vector that directs high levels of expression of cloned genes in mammalian cells. Proc Natl Acad Sci USA 85: 9431–9435PubMedGoogle Scholar
  25. 25.
    Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, Salvesen GS Pickup DJ (1992) Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 β converting enzyme. Cell 69: 597–604PubMedGoogle Scholar
  26. 26.
    Shida H, Tanabe K, Matsumoto S (1977) Mechanism of virus occlusion into A-type inclusion during poxvirus infection. Virology 76: 217–233PubMedGoogle Scholar
  27. 27.
    Shida H, Tochikura T, Sato T, Konno T, Hirayoshi K, Seki M, Ito Y, Hatanaka M, Hinuma Y, Sugimoto M, Takahashi-Nishimaki F, Maruyama T, Miki K, Suzuki K, Morita M, Sashiyama H, Hayami M (1987) Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 6: 3379–3384PubMedGoogle Scholar
  28. 28.
    Spriggs MK, Hruby DE, Maliszewski CR, Pickup DJ, Sims JE, Buller RML, Vanslyke J (1992) Vaccinia and cowpox virus encode a novel secreted interleukin-1-binding protein. Cell 71: 145–152PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • N. Jin
    • 1
  • S. Funahashi
    • 2
  • H. Shida
    • 1
  1. 1.Institute for Virus ResearchKyoto UniversityKyoto
  2. 2.Corporate Research and Development LaboratoryTonen CorporationSaitamaJapan

Personalised recommendations